Drug Profile
PRO 367
Latest Information Update: 19 Jun 2020
Price :
$50
*
At a glance
- Originator Progenics Pharmaceuticals
- Class Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals has been acquired by Lantheus Holdings
- 21 Aug 2007 Discontinued - Phase-I for HIV infections treatment in USA (unspecified route)
- 29 Aug 2000 Phase-I clinical trials for HIV infections treatment in USA (Unknown route)